Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and tremelimumab in recurrent or metastatic PD-L1-negative head and neck squamous cell carcinoma
2014-003717-29Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Durvalumab monotherapy, Tremelimumab monotherapy and Durvalumab + tremelimumab (3 arms). Primary endpoint: Overall response rate. Started Jun 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2014-003717-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003717-29.